Clinical Research Division, Fred Hutch
Dr. Guang-Shing Cheng is a pulmonologist who focuses on improving outcomes for cancer patients who have respiratory failure and lung complications related to their cancer treatments. She is developing new ways to prevent lung damage and improve lung function in these patients. Dr. Cheng’s main interest is bronchiolitis obliterans syndrome, a serious complication of blood stem cell transplantation. She also studies the role of respiratory viruses and other infectious pathogens in lung disease in patients with compromised immune systems.
Associate Professor, Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine
University of Washington
Attending Physician, Pulmonary / Critical Care Medicine
Seattle Cancer Care Alliance (SCCA)
B.A. (Biology): Harvard University; Cambridge, MA; 1996
M.D. (Medicine): University of California at San Francisco; San Francisco, CA; 2001
Internship/Residency (Internal Medicine): Yale-New Haven Hospital; New Haven, CT; 2005
Pulmonary/Critical Care Fellowship: Yale University School of Medicine; New Haven, CT; 2008
Postdoctoral Fellowship: University of Pennsylvania School of Medicine; Philadelphia, PA; 2009
Dr. Cheng is a pulmonologist and critical care specialist who sees patients at the SCCA with respiratory problems including complications of their cancer treatment. She also has expertise in diagnosing lung nodules due to a variety of causes, including lung cancer. She attends in the Pulmonary Consult Service and the Lung Cancer Early Detection and Prevention Clinic at SCCA. Dr. Cheng performs bronchoscopies for the diagnosis of respiratory infections and lung cancer. She also attends in the Intensive Care Unit at the University of Washington.
She has authored multiple manuscripts in peer-reviewed journals about BOS and other lung complications after HCT. She edited an issue of Clinics in Chest Medicine on pulmonary disease in non-pulmonary malignancies. In addition, she has authored two chapters in Murray and Nadel, a definitive test on pulmonary disorders.
Dr. Cheng’s goal is to improve outcomes for stem cell transplant patients with infectious and non-infectious lung disease. Her research focuses on bronchiolitis obliterans syndrome (BOS), which is a complication of chronic graft-versus-host disease in patients who have received HCT. Currently, there are no therapies that routinely reverse the course of the disease. Dr. Cheng is working to develop early detection and prevention strategies for HCT patients, including the use of wireless handheld spirometry monitoring, which may lead to earlier treatment. She is also involved in multicenter trials testing new drugs for the treatment of BOS and other lung diseases after HCT. She is investigating the relationship between respiratory viral infection and the development of lung disease in these patients.
The Media Relations team at Fred Hutch is available to assist members of the news media who would like to arrange interviews with faculty.
Email email@example.com or call 206.667.2210.